Bayer
The 340B program has “strayed far from its original purpose, creating a profit stream that is enriching middlemen versus benefiting patients,” Bayer says.

Bayer: 340B “Is Enriching Middlemen Versus Benefitting Patients”

While the 340B program “has merit when used as intended,” it has “strayed far from its original purpose, creating a profit stream that is enriching middlemen versus benefitting patients,” drug manufacturer Bayer told 340B Report yesterday.

Bayer gave the statement to 340B Report late yesterday in response to a request to elaborate on its decision to impose conditions on 340B pricing when hospitals use contract pharmacies. Its statement arrived too late to be included in our Feb. 1 article about its new policy.

While the 340B program “has merit when used as intended,” it has strayed far from its original purpose, creating a profit stream that is enriching middlemen versus benefitting patients,” drug manufacturer Bayer told 340B Report yesterday.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer